Used in cancer immunotherapy to block the CD73 enzyme, which plays a key role in suppressing immune responses within the tumor microenvironment. By inhibiting CD73, this antibody helps restore the activity of T cells and enhances the body's ability to fight tumors. It is being investigated in clinical trials, often in combination with other immunotherapies like PD-1/PD-L1 inhibitors, for the treatment of solid tumors including non-small cell lung cancer and triple-negative breast cancer. Its application aims to overcome immune evasion by cancer cells and improve patient response to immunotherapy.